TMO

You Won't Regret Reading the Facts on Thermo Fisher Scientific.

Shares of Thermo Fisher Scientific have moved -2.7% today, and are now trading at a price of $564.5. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 546,321 compared to the stock's average volume of 1,210,488.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. Based in Waltham, United States the company has 130,000 full time employees and a market cap of $217,726,517,248. Thermo Fisher Scientific currently offers its equity investors a dividend that yields 0.2% per year.

The company is now trading -12.97% away from its average analyst target price of $648.64 per share. The 22 analysts following the stock have set target prices ranging from $505.0 to $711.0, and on average give Thermo Fisher Scientific a rating of buy.

Over the last year, TMO shares have gone down by -0.1%, which represents a difference of 5.0% when compared to the S&P 500. The stock's 52 week high is $611.06 per share and its 52 week low is $475.77. With its gross margins declining an average -1.6% over the last four years, Thermo Fisher Scientific may not have a strong enough business to reverse this trend.

Date Reported Revenue ($ k) Cost of Revenue ($ k) Gross Margins (%) YoY Growth (%)
2022-12-31 44,915,000 25,415,000 43.42 -15.85
2021-12-31 39,211,000 18,977,000 51.6 0.72
2020-12-31 32,218,000 15,713,000 51.23 10.65
2019-12-31 25,542,000 13,715,000 46.3 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS